C(OC([N:8]1[CH2:13][CH:12]([CH3:14])[N:11]([CH2:15][C:16]2[CH:25]=[C:24]3[C:19]([C:20]([NH2:26])=[N:21][CH:22]=[N:23]3)=[CH:18][CH:17]=2)[C:10](=[O:27])[CH:9]1[CH2:28][CH2:29][CH3:30])=O)(C)(C)C.Cl>CCOC(C)=O>[NH2:26][C:20]1[C:19]2[C:24](=[CH:25][C:16]([CH2:15][N:11]3[CH:12]([CH3:14])[CH2:13][NH:8][CH:9]([CH2:28][CH2:29][CH3:30])[C:10]3=[O:27])=[CH:17][CH:18]=2)[N:23]=[CH:22][N:21]=1To a solution of 4-[4-amino-quinazolin-7-ylmethyl]-5-methyl-3-oxo-2-propyl-piperazine-1-carboxylic acid tert-butyl-ester (0.91 g, 2.2 mmol) in EtOAc (40 mL) is bubbled HCl (gas) for 5 min. at 0° C. After this time, the solution is stirred at ambient temperatures for 15 min. The solution is concentrated. The residue is purified by column chromatography eluting with 1:5:100 NH4OH/MeOH/CH2Cl2. The title compound (0.5 g) is obtained as a white solid. 1H NMR (300 MHz, CDOD) δ8.40 (s, 1H), 8.04 (d, 1H), 7.52 (s, 1H), 7.36 (m, 1H), 5.10 (d, 1H), 4.45 (d, 1H), 3.55 (m, 2H), 3.10 (m, 1H), 2.81 (m, 1H), 1.90 (m, 1H), 1.72 (m, 1H), 1.44 (m, 2H), 1.29 (d, 3H), 0.96 (m, 3H).
Wird geladen…